Clinical trials in Nashville, TN

311 recruiting studies have a site in or near Nashville, TN, Tennessee.

Top conditions here

All conditions

Showing 40 of 311 studies

RecruitingPhase 3NCT07654374

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Nashville, TN · +73 more sites

RecruitingPhase 2NCT07752979

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Sponsor: AbbVie

Bristol, TN · Knoxville, TN · +56 more sites

RecruitingPhase 3NCT03394365

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Sponsor: Pierre Fabre Medicament

Memphis, TN · Nashville, TN · +38 more sites

RecruitingPhase 1 / Phase 2NCT06162221

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Sponsor: Revolution Medicines, Inc.

Memphis, TN · Nashville, TN · +27 more sites

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Knoxville, TN · Memphis, TN · Nashville, TN · +112 more sites

RecruitingPhase 4NCT06972056

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

Sponsor: Mayo Clinic

Nashville, TN · +36 more sites

RecruitingPhase 3NCT07190209

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Sponsor: Sanofi

Nashville, TN · +74 more sites

RecruitingPhase 3NCT05980949

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Nashville, TN · +147 more sites

RecruitingPhase not listedNCT06297291

Global Paradise System US Post Approval Study

Sponsor: ReCor Medical, Inc.

Nashville, TN · +45 more sites

RecruitingPhase 1NCT06465069

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Sponsor: Eli Lilly and Company

Nashville, TN · +21 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Chattanooga, TN · Knoxville, TN · Memphis, TN · +51 more sites

RecruitingPhase 3NCT06819878

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Sponsor: Hoffmann-La Roche

Germantown, TN · Nashville, TN · +93 more sites

RecruitingPhase 1NCT06846606

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Sponsor: Auron Therapeutics, Inc.

Nashville, TN · +8 more sites

RecruitingPhase 3NCT07365995

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Sponsor: BioNTech SE

Nashville, TN · +19 more sites

RecruitingPhase 3NCT07674654

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

Sponsor: Kallyope Inc.

Chattanooga, TN · Nashville, TN · +110 more sites

RecruitingPhase 1NCT03460977

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Sponsor: Pfizer

Nashville, TN · +43 more sites

RecruitingPhase 1NCT06120283

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Sponsor: BeOne Medicines

Nashville, TN · +8 more sites

RecruitingPhase 1NCT06545331

Study of XB010 in Subjects With Solid Tumors

Sponsor: Exelixis

Nashville, TN · +15 more sites

RecruitingPhase 2 / Phase 3NCT06712316

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Sponsor: BioNTech SE

Knoxville, TN · Memphis, TN · Nashville, TN · +50 more sites

RecruitingPhase 1 / Phase 2NCT07020221

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Sponsor: Verastem, Inc.

Nashville, TN · +12 more sites

RecruitingPhase 3NCT07177352

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Sponsor: Hoffmann-La Roche

Knoxville, TN · Nashville, TN · +66 more sites

RecruitingPhase 3NCT07424404

A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Nashville, TN · +55 more sites

RecruitingPhase 1NCT07824349

JUR-003 in Adult Patients With Metastatic Prostate Cancer

Sponsor: Juri Biosciences, Inc.

Nashville, TN · +3 more sites

RecruitingPhase 2NCT07837973

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

Sponsor: Alveus Therapeutics, Inc.

Nashville, TN · +19 more sites

RecruitingPhase 3NCT05156398

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Sponsor: Pfizer

Nashville, TN · +55 more sites

RecruitingPhase 3NCT07028853

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Sponsor: Pfizer

Chattanooga, TN · +124 more sites

RecruitingPhase 1NCT07462377

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Sponsor: EpiBiologics

Nashville, TN · +5 more sites

RecruitingPhase not listedNCT02071134

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

Sponsor: Boston Scientific Corporation

Nashville, TN · +28 more sites

RecruitingPhase 1 / Phase 2NCT05786924

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Sponsor: Institut de Recherches Internationales Servier

Nashville, TN · +20 more sites

RecruitingPhase 3NCT06136559

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Sponsor: Merck Sharp & Dohme LLC

Chattanooga, TN · Nashville, TN · +47 more sites

RecruitingPhase 3NCT06307652

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Sponsor: AstraZeneca

Jackson, TN · Knoxville, TN · Memphis, TN · +163 more sites

RecruitingPhase 3NCT06307665

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

Sponsor: AstraZeneca

Nashville, TN · +119 more sites

RecruitingPhase 3NCT06430801

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Sponsor: Merck Sharp & Dohme LLC

Nashville, TN · +85 more sites

RecruitingPhase 3NCT06646276

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Sponsor: Bristol-Myers Squibb

Nashville, TN · +19 more sites

RecruitingPhase 3NCT06736574

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Sponsor: Cytokinetics

Germantown, TN · Knoxville, TN · Nashville, TN · +85 more sites

RecruitingPhase 3NCT06841354

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Sponsor: Merck Sharp & Dohme LLC

Nashville, TN · +37 more sites

RecruitingNot applicableNCT06898515

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

Sponsor: Reprieve Cardiovascular, Inc

Nashville, TN · +34 more sites

RecruitingNot applicableNCT06965504

INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery

Sponsor: Abiomed Inc.

Nashville, TN · +16 more sites

RecruitingPhase 3NCT06966700

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Sponsor: Merck Sharp & Dohme LLC

Knoxville, TN · Nashville, TN · +61 more sites

RecruitingPhase 3NCT07007312

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Sponsor: Kura Oncology, Inc.

Memphis, TN · Nashville, TN · +41 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.